News & Updates

1112, 2020

Updated Outcome and Treatment Benefit Data from MINDACT Study Reinforce Real-World Value of MammaPrint for Clinical Low Risk Breast Cancer Patients at SABCS 2020

December 11th, 2020|

IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – December 11, 2020 – Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that additional data from its groundbreaking MINDACT study will be highlighted Read More